An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. [electronic resource]
Producer: 20120110Description: 734-43 p. digitalISSN:- 1476-5500
- Adenocarcinoma -- drug therapy
- Adenoviruses, Human -- genetics
- Animals
- Antineoplastic Agents -- therapeutic use
- Cell Line, Tumor
- Cell Survival
- Combined Modality Therapy
- Cytopathogenic Effect, Viral
- Deoxycytidine -- analogs & derivatives
- Fluorouracil -- therapeutic use
- Gene Deletion
- Gene Expression Regulation, Viral -- drug effects
- Humans
- Kaplan-Meier Estimate
- Mice
- Mice, Inbred C57BL
- Mice, Nude
- Oncolytic Virotherapy
- Oncolytic Viruses -- genetics
- Pancreatic Neoplasms -- drug therapy
- Receptors, Virus -- metabolism
- Retinoblastoma Protein -- metabolism
- Virus Replication -- genetics
- Xenograft Model Antitumor Assays
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.